An analysis of the safety and efficacy of rivaroxaban (Riv) and low molecular weight heparin (LMWH) in gastrointestinal cancer-associated venous thromboembolism (GICA-VTE).

374Background: CAVTE has a significant morbidity and mortality burden, with higher incidence and bleeding complications of anticoagulation (AC) in GICA. Current guidelines prefer LMWH, and recently added Riv, as an alternative standard after the SELECT-D trial (S-D). There is a paucity of data comparing the safety and efficacy of other DOACs in pts with GICA. We indirectly compared the safety and efficacy of Riv vs LMWH of our pts with active GICA-VTE at the University of Arizona Cancer Center (UACC) to the S-D GI-population. Methods: Pts with biopsy proven GICA, symptomatic or incidental VTE, and 6 months or more treatment with Riv or LMWH at UACC from 11/2013 - 12/2017 were retrospectively reviewed. S-D GICA data was extracted. Primary efficacy outcome was recurrent deep vein thrombosis (DVT), nonfatal pulmonary embolism (PE), or fatal PE. Safety outcomes for major bleeding (MB) include Hg drop ≥ 2 g/dL, transfusion of ≥ 2 units PRBC, bleeding in critical site, or bleeding contributing to death. Fisher ...